Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Ampersand Biomedicines

Request full access

Programming medicines to act only where needed

Boston, United StatesFounded 2020Biotech & Life Sciences

About Ampersand Biomedicines

Ampersand Biomedicines is a biotechnology company focused on developing modular therapeutics that are localized to specific target tissues, thereby enhancing efficacy and safety in disease treatment. The company operates in the precision medicine market, addressing the critical challenge of on-target, off-tissue toxicity in drug development. Ampersand's primary clients include pharmaceutical companies and healthcare providers seeking advanced therapeutic solutions. The business model revolves around creating and programming therapeutics that combine a localizing element for disease-specific precision with an actuator for restoring healthy biology. Ampersand generates revenue through partnerships, licensing agreements, and potentially direct sales of its proprietary therapeutics. The company recently secured $50 million in funding from Flagship Pioneering to advance its platform and expand its therapeutic offerings.

Source: Dealroom company data

At a glance

Status
Operational
Employees
72
Open positions
2
Dealroom signal
89.0/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Precision Medicine, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Investment activity
1 company, latest Jan 2024
Capital deployed
—
Preferred round
ACQUISITION

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Mar 2025 $65M $260M Flagship Pioneering · Eli Lilly ↗
LATE VCOther financing Mar 2023 $50M $200M Flagship Pioneering ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Ampersand Biomedicines website traffic

Latest recorded traffic for Ampersand Biomedicines is 4.2K monthly website visits, down 10.6% over the last three months. Ampersand Biomedicines's team grew 20% over the past year.

Latest monthly visits4.2K 3-month web change-10.6% 1-year team growth+20%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Ampersand Biomedicines in the Boston ecosystem

Live from Dealroom

The Ampersand Biomedicines office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Eli Lilly

Series B and later1 investor entered at this stage

Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇺🇸 United States74.2%
🇨🇿 Czech Republic22.6%
🇩🇪 Germany1.6%
🇵🇹 Portugal1.6%
4 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Ampersand Biomedicines on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Ampersand Biomedicines’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.